Αρχειοθήκη ιστολογίου

Δευτέρα 19 Φεβρουαρίου 2018

Dupilumab: A review of its use in the treatment of atopic dermatitis

Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis characterized by a T helper 2 (Th2) immune response phenotype and may be associated with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-4/13 is effective in reducing Th2 response. Dupilumab has recently been approved in the United States and Europe for the treatment of adult patients with moderate-to-severe AD.

http://ift.tt/2C6sBz3

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου